News & Events

KOL Webinar

Hosted by Pharma Two B (Private)

Thursday, January 27, 2022
11:00 AM – 12:00 PM EST

The webinar will feature a presentation by Parkinson’s Disease (PD) Key Opinion Leaders Robert Hauser, MD, MBA and C. Warren Olanow, MD, along with Sheila Oren, MD, MBA Pharma Two B CEO, to discuss the recently announced positive results from the pivotal Phase III Study of P2B001 in early Parkinson’s disease. This will be followed by a company update.

P2B001, an investigational drug, is a novel, once daily capsule of
low dose, extended-release combination of pramipexole and rasagiline, developed
for the treatment of early PD. The Company is planning to file an NDA for P2B001 in
2022.

Dr. Hauser and Dr. Olanow will discuss the unmet medical need for early-stage PD and the and will present the efficacy and safety profile of P2B001.

A live question and answer session will follow.

IMPORTANT INFORMATION
Registration information 
You are required to register in advance for the webcast. For those who are unable to listen at this time, a replay of the call will be available by clicking here.
Q&A information
If you would like to ask a question during the live Q&A, please submit your request to questions@lifesciadvisors.com.
SPEAKER BIOGRAPHIES
Robert A. Hauser, MD, MBA Robert A. Hauser, MD, MBA is a Professor of Neurology, Molecular Pharmacology, and Physiology at the University of South Florida Morsani College Of Medicine, in Tampa. He serves as Director of the Clinical Signature Interdisciplinary Program in Neuroscience and as Director of the USF Health Byrd Parkinson’s Disease and Movement Disorders Center.
Dr. Hauser earned a medical degree from Temple University School of Medicine, in Philadelphia, Pennsylvania, and completed neurology training at the Eastern Virginia Graduate School of Medicine, Norfolk General Hospital. Dr. Hauser completed a fellowship in Movement Disorders at the University of South Florida and became Center Director in 1994. Dr. Hauser has authored or co-authored more than 200 peer-reviewed publications. He lectures frequently at scientific meetings around the world. He is Past Chairman of the Interventional Neurology Section of the American Academy of Neurology, has served on the executive committee of the Parkinson Study Group, and is a member of the steering committee for the NIH sponsored Neuroprotective Exploratory Trials in Parkinson’s Disease program (NET-PD). His primary research interest is in the development of new medical and surgical treatments for Parkinson’s disease, tremor, dystonia, and restless legs syndrome.
C. Warren Olanow, MD C. Warren Olanow, MD has been Chief Executive Officer of CLINTREX since its founding in 2008. He is the former Henry P. and Georgette Goldschmidt Professor and Chairman of the Department of Neurology, at the Mount Sinai School of Medicine in New York City, and currently serves as Professor Emeritus in the Department of Neurology and in the Department of Neuroscience at this institution.
He received his medical degree from the University of Toronto and performed his neurology training at the New York Neurological Institute at Columbia University. He is a Past President of the Movement Disorder Society, Past President of the International Society of Motor Disturbances, Past Treasurer of the American Neurological Association, and past Editor-in-Chief of the journal Movement Disorders. He was a founding member and served on the initial Executive Committee of the Parkinson Study Group. His research has focused on the cause and treatment of PD and other neurodegenerative diseases. He has led multiple pivotal clinical trials and interacted with regulatory agencies leading to the approval of Pergolide, DBS for tremor, DBS for PD, Safinamide, levodopa/carbididopa intestinal gel, and the apomorphine sublingual strip. He also led important experimental clinical trials including the delayed start study (ADAGIO), the STRIDE-PD study, Fetal nigral transplantation, and gene delivery of neurturin. He has served on dozens of Scientific Advisory Committees for pharmaceutical and biotech companies, including the Michael J. Fox Foundation, and the National Space Board Research Institute. He is an honorary professor at University College London (Royal Free Hospital), an honorary member of the French Neurological Society, and an honorary fellow of the Royal College of Physicians in the United Kingdom (FRCP). He is the recipient of the 2013 movement disorder research award from the American Academy of Neurology and the lifetime achievement award from the International Parkinson and Movement Disorder Society.